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Abstract
Summary This primary care database survey evaluated wheth-
er osteoporotic women treated with bisphosphonates were
more adherent to monthly than to weekly treatment. Both
compliance (medication possession ratio [MPR]) and persis-
tence (time to discontinuation) were superior in the monthly
ibandronate treatment group. Better control of fracture risk may
thus be achieved using monthly treatment regimens.
Introduction Treatment adherence in osteoporosis is poor.
The objective of this study was to evaluate whether
monthly bisphosphonate treatment provided superior
adherence than weekly treatment.
Methods We analysed medical claims from a national
prescription database (Thales). All women aged >45 years
receiving a first prescription of monthly ibandronate or
weekly bisphosphonates in 2007 were included. Treatment
adherence was monitored from initial prescription until
January 2008. Compliance was measured by the MPR and
persistence by the time from treatment initiation to
discontinuation. Multivariate analysis was used to identify
variables independently associated with adherence.
Results Twelve-month persistence rates were 47.5% for
monthly ibandronate and 30.4% for weekly bisphosphonates.
Compliance was significantly higher in the monthly cohort
(MPR=84.5%) than in the weekly cohort (MPR=79.4%).
After adjustment for potential confounding variables, women
with monthly regimens were 37% less likely to be non-
persistent (HR=0.63 [0.56–0.72]) and presented a 5% higher
meanMPR(84.5%versus79.3%,p<0.001) than women with
weekly regimens. Other major factors associated with
improved adherence were previous densitometry and calcium
or vitamin D supplementation (p<0.01).
Conclusions Adherence to bisphosphonates may be supe-
rior for monthly treatment than for weekly treatment and
may thus provide improved fracture protection.
Keywords Adherence.Bisphosphonates.Compliance.
Osteoporosis.Persistence.Treatmentregimen
Introduction
Low long-term adherence to drugs by asymptomatic
patients with chronic diseases is an important public health
issue. Indeed, a report published by the World Health
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only 50% of patients with chronic diseases adhered to their
recommended treatment regimens [1]. A community survey
performed in Canada has indicated that nonadherence to
medication in general was associated with adverse health
outcomes such as hospitalisation, emergency department
visits or death [2].
One field of medicine in which treatment adherence is a
major issue is antiresorptive therapy to prevent osteoporotic
fractures [3]. A recent expert consensus group in osteoporo-
sis [4] described adherence as a general term encompassing
both compliance and persistence. Compliance was defined as
the extent to which a patient acts in accordance with the
prescribed interval and dose of a given treatment regimen,
whereas persistence was defined as the cumulative time from
initiation to discontinuation of therapy. Compliance is
frequently assessed by measuring the medication possession
ratio (MPR), defined as the ratio between the actual interval
between prescription refills and the anticipated interval
assuming full compliance [5].
Oral bisphosphonates are effective treatments of osteo-
porosis, and several large randomised clinical trials have
shown that they can reduce the risk of osteoporotic
fractures by an average of 50% [6]. However, the
effectiveness of bisphosphonates is compromised by poor
adherence to treatment, since a significant proportion of
patients abandon their treatment within 6 months of
initiation [7] and more than half stop treatment within the
first year [8–10]. Low adherence reduces the effectiveness
of treatment and, in consequence, increases the risk of
fracture [10–13] and resulting healthcare use and costs [14].
A recent Belgian database analysis [15] showed that the
relative reduction in the risk of hip fracture was 60% for
women who were persistent with bisphosphonate treatment
compared to those who were non-persistent. In addition, for
each incremental decrease of 1% in compliance, as
measured by the MPR, the risk of hip fracture increased
by 0.4%.
For antiresorptive treatments for osteoporosis, public
awareness of the risks associated with osteoporosis, the
absence of a simple ‘read-out’ of the efficacy of medica-
tion, gastrointestinal side effects and the constraints
associated with treatment may all contribute to suboptimal
adherence [13, 16, 17]. In particular, the regimen recom-
mended for bisphosphonates, which requires overnight
fasting before medication and the necessity of remaining
upright for at least 30 min after having taken the
medication, is a major limitation to the acceptability of
treatment, especially when treatments need to be taken
daily. For this reason, formulations of bisphosphonates
allowing weekly and, subsequently, monthly administration
have been developed with the aim of reducing the
constraints associated with dosing.
Indeed, a number of studies have shown that adherence to
weekly administration is superior to that of daily dosing. For
example, a study of US prescriptions claims demonstrated a
significantly higher MPR (69.2% versus 57.6%; p<0.0001)
and persistence rate (44.2% versus 31.7%; p<0.0001)
associated with the use of once-weekly alendronate com-
pared to once-daily alendronate or risedronate over the
12 months following the initial prescription [18]. A
pharmacy database study in the US also reported that only
around one-third of patients taking daily bisphosphonates
and around one-half using weekly administration achieved
adequate adherence. Such findings have been reiterated in
other healthcare systems such as France and the UK [19, 20].
More recently, monthly administration of ibandronate
has been developed with the aim of increasing adherence
further [21]. However, to date, there is little published
information on whether adherence to a monthly regimen is
indeed superior. The PERSIST study [22] has compared
6-month persistence rates in women randomised either to
monthly ibandronate together with a patient support
programme or to weekly alendronate and reported higher
persistence rates in the former group (56.6% versus 38.6%;
p<0.0001). However, the relative contributions of the
dosing regimen and the patient support programme in
improving persistence cannot be identified in this study. On
the other hand, a study in the US reported poorer adherence
in women receiving monthly ibandronate than in a
historical control group treated with weekly risedronate
[23]. This study is difficult to interpret since the two groups
were not compared at the same time using the same
protocol and because the follow-up period did not start
when treatment was initiated. Given the limited amount of
comparative data on adherence to monthly bisphosphonate
treatment, we have undertaken a pharmacoepidemiological
study whose objective was to compare adherence to weekly
and monthly bisphosphonate therapy in a cohort of post-
menopausal women.
Materials and methods
This was a retrospective pharmacoepidemiological study
conducted within the context of primary healthcare in
France during 2007 using medical claims data from a
national prescription database. We examined the data
collected during the year preceding and the year following
the introduction of ibandronate in France (January 2007).
Data source
We used medical claims from the Thales longitudinal
prescription database. Thales is a computerised network of
1,200 general practitioners (GPs) who contribute exhaustive
146 Osteoporos Int (2010) 21:145–155anonymous data on patient consultations and treatment to a
centralised electronic database, allowing subsequent follow-
up of outcomes. Analyses performed using this database
have been approved by the Commission Nationale de
l'Informatique et des Libertés.
GPs participating in the Thales network are selected to
be representative of the French GP population according
to three main criteria, namely, geographical area, age and
gender. Activity and prescription habits of the panel have
also been compared a posteriori with national data and
s h o w nt ob er e p r e s e n t a t i v e[ 24]. The database includes
routinely collected records for >1.6 million patients. Since
2005, each patient is required by law to have a single
referent GP in order to limit medical roaming and multiple
consultations for the same reason. Patient data collected
by GPs since 2005 can thus be considered exhaustive and
non-redundant.
For each patient, information on disease status and
medication prescription is entered directly into the
database by the physician at the time of the consultation.
N oi n f o r m a t i o na st ot h er e a s o n sf o rm a k i n gi n d i v i d u a l
diagnostic or prescription choices is, however, provided.
The disease status is encoded using terms from a specific
thesaurus of symptoms and disease entities adapted from
the International Classification of Diseases (ICD-10)
system. Prescription data contain the dispensed drug
name (commercial and international common denomina-
tion), the Anatomical Therapeutic Chemical (ATC)
classification category, dose regimens and prescription
duration.
Study population
We identified all female patients in the Thales database,
aged over 45 years who had received a first prescription
of either a weekly or a monthly bisphosphonate treat-
ment between January 2007 (date of introduction of
ibandronate in France) and the end of 2007. The index
date for the analysis was the date of the initial
prescription. These patients were followed up prospec-
tively until January 2008 to evaluate treatment adher-
ence. A retrospective analysis was also performed
covering the period from January 2006 to January 2007
in order to identify subjects who had been prescribed any
other osteoporosis treatment (bisphosphonates, selective
oestrogen receptor modulators or strontium ranelate)
during the 12-month period prior to the index prescrip-
tion, who were excluded. In order to ensure complete-
ness of data, patients were also required to have
consulted their GP at least twice a year for any reason
during the retrospective and prospective follow-up
periods (January 2006–January 2008). In order to restrict
the analysis to patients who discontinued treatment
definitively, we excluded any women who subsequently
switched treatment from one bisphosphonate to another
during the follow-up period. Study subjects were then
assigned to one of two cohorts on the basis of their
treatment administration regimen, namely, a weekly
(risedronate 35 mg or alendro n a t e7 0m gw i t ho rw i t h o u t
vitamin D) or a monthly (ibandronate 150 mg) cohort.
Within the weekly cohort, women receiving alendronate
and those receiving risedronate were pooled, on the basis
that the two bisphosphonates present side effect profiles
and risks of discontinuation [25].
Data collection
Data were collected on demographic and clinical variables
at the time of the index prescription. Information on
comorbidities and other medication use or clinical exami-
nations at the time of the index prescription and during the
follow-up period were recorded for each patient. All
prescriptions for bisphosphonates during the follow-up
period were identified. Information on fracture history at
inclusion and incident fractures during the follow-up period
was also retrieved from the database. Information on
fracture site and radiological evaluation was, however, not
systematically available.
Outcome measures
The outcome measures of the study were MPR and
persistence. MPR was defined as the duration of all
filled prescriptions divided by the follow-up period.
Persistence was measured by the time from initiation of
therapy to discontinuation. As required for persistence
analysis, a limit on the number of days allowed between
refills, the permissible gap (PG), was prespecified.
Patients who stopped their treatment for a duration
l o n g e rt h a nt h eP Gw e r ec o n s i d e r e dt oh a v ed i s c o n -
tinued, even if they subsequently restarted treatment. In
many previous studies, the PG applied to weekly
bisphosphonates was specified empirically at 30 days
[9, 26–28]. Cramer et al. [5] recently proposed a less
arbitrary method based on the pharmacological proper-
ties of the drug and the treatment situation in which the
PG definition should take into account the maximum
allowable period for which patients could go untreated
without anticipating reduced or suboptimal outcomes.
As specified in the product labelling, the recommended
acceptable dosing window for monthly ibandronate
(21 days) is 15 days longer than that of weekly
bisphosphonates (6 days). For this reason, a prespecified
PG of 45 days for the monthly regimen and of 30 days
for the weekly regimen was considered acceptable, as
previously implemented in a US database analysis [29].
Osteoporos Int (2010) 21:145–155 147We also performed a sensitivity analysis in order to test
the influence of the definition of PG on the persistence
results in which an identical PG of 30, 45 or 60 days was
allowed for both formulations.
Statistical analysis
The demographic and clinical characteristics of patients
included in the two cohorts were compared using the χ
2
test or Fisher’s exact test for categorical variables and
the Kruskal–Wallis test for continuous variables.
Persistence rates were evaluated using Kaplan–Meier
survival analysis and compared between the two cohorts
using the log-rank test in a Cox proportional hazards model.
For MPR, the two cohorts were described by mean MPR
values and by distribution of patients across MPR classes.
This analysis was performed on the entire study population.
Since the profiles of patients in the weekly and
monthly cohorts were potentially different and con-
founding factors could thus contribute to the difference
in persistence and in MPR between the two cohorts,
these were taken into account by constructing a
propensity score [30]. This score included all demographic,
clinical and treatment variables recorded in the database
and was calculated using multivariate logistic regression.
Each patient was attributed a propensity score that
represented the probability of receiving monthly rather
than weekly bisphosphonate treatment with respect to the
pattern of potential confounding factors presented. The
cohorts were compared by means of hazard ratios for
persistence and least squares means for compliance. These
parameters are presented with their 95% confidence
intervals (95%CI), both unadjusted and after adjustment
by the propensity score. With respect to persistence, a
sensitivity analysis was performed in order to determine
the influence of the definition of the permissible gap on
the results obtained.
All demographic and clinical variables were tested for
their association with MPR and persistence using multivar-
iate logistic regression analysis. This analysis was restricted
to women for whom at least 6 months' follow-up was
available since the initial prescription of a bisphosphonate.
For persistence, the dependent variable to be explained was
reaching a persistence of at least 6 months, and for MPR,
reaching an MPR of at least 68%. These thresholds were
chosen since they had been identified as the best predictors
of fracture risk in a previous case–control analysis of
women treated with bisphosphonates in the Thalès database
[31]. Variables were selected serially in an ascending
manner, with a cut-off probability threshold of 0.05 at each
step. The variables retained in the stepwise model were
then entered into a final multivariate logistic regression in
order to compute odds ratios.
All analyses were performed using SAS® software
version 8.2 (SAS, Cary, USA) on Windows.
Results
Participating investigators
In the Thales database, 1,073 physicians provided patients
to the study, of whom 541 prescribed both monthly and
weekly regimens, 123 only monthly regimens and 409 only
weekly regimens. These three groups of physicians did not
differ with respect to age, gender or place of practice in
France (data not shown).
Study sample
A total of 3,157 women were prescribed a weekly or
monthly bisphosphonate treatment for the first time
during the reference period (January 2007 to January
2008). Of these, 63 women were under 45 years and
were excluded. In addition, 104 subjects (82 in the
weekly group and 22 in the monthly group) subse-
quently switched to another bisphosphonate treatment
and were also excluded from the study sample (Fig. 1).
The analysis was thus performed on the remaining 2,990
women, of whom 1,989 received weekly bisphosphonate
(581 alendronate and 1,408 risedronate) and 1,001
monthly ibandronate. Given that the demographic and
clinical characteristics of women receiving alendronate
and risedronate were comparable (data not shown), these
two groups were not analysed separately but pooled in a
single weekly regimen group.
In the two cohorts, data was available over at least
6 months of follow-up since the initial prescription of a
bisphosphonate for a total of 1,889 women. This subgroup
was used for the analysis of variables associated with good
adherence.
Patient characteristics in the two treatment cohorts
The demographic and clinical characteristics of the study
sample at the time of the index prescription are presented in
Table 1. Patients receiving monthly ibandronate were
younger than patients in the weekly cohort and had less
frequent osteoporotic fractures before treatment initiation.
At initiation, bone densitometry had been performed more
frequently in the monthly cohort than in the weekly cohort
(p=0.003), but there was no difference in the two cohorts
for bone mass densitometry (BMD) assessments during the
follow-up.
The most common comorbidities were arterial hyper-
tension (44.5%), other rheumatic diseases (31.5%),
148 Osteoporos Int (2010) 21:145–155malignant neoplasms (28.0%) and neurological diseases
(27.1%). The only condition whose distribution differed
significantly between the monthly and weekly cohorts
was rheumatoid arthritis (1.6% versus 2.7%, respective-
ly), although this was only reported in 70 patients
overall.
The most frequently prescribed comedication classes were
tranquillisers (34.7%), anti-inflammatory and anti-rheumatic
drugs (31.8%) and lipid-reducing agents (29.5%). No differ-
ence in prescription rates between cohorts was observed for
these medication classes. However, the prescription of 13
othercomedicationclassesdiddiffersignificantlybetweenthe
Women starting
bisphosphonate treatment
N = 3,157
Post-menopausal
osteoporosis
N = 3,094
Monthly regimen
(100% ibandronate)
N = 1,001
Weekly regimen
(70.8% RIS; 29.2% ALEN)
N = 1,989
< 45 years
N = 63
Within
class switch
N = 104
N = 601 N = 1,288
≥ 6 months follow-up  ≥ 6 months follow-up
Fig. 1 Flowchart illustrating
selection of patients evaluated in
the database. RIS risedronate,
ALEN alendronate
Table 1 Demographic and clinical variables in the study sample
Monthly ibandronate (N=1,001) Weekly bisphosphonates (N=1,989) p value
Age (years) 68.8±10.3 70.4±10.3 <0.001*
BMI (kg/m
2) 24.9±4.4 24.9±4.8 0.890
Height (cm) 158±7 158±6 0.128
Weight (kg) 62.5±11.6 62.2±12.3 0.375
Known smoker, n (%) 35 (3.5) 74 (3.7) 0.836
Known alcohol problem, n (%) 26 (2.6) 52 (2.6) 1.000
Previous osteoporotic fracture, n (%) 325 (32.5) 810 (40.7) <0.001*
BMD availability, n (%)
Before treatment initiation 186 (18.6) 288 (14.5) 0.003*
After treatment initiation 32 (3.2) 61 (3.1) 0.845
Comorbidities, n (%)
Any 875 (87.4) 1,729 (86.9) 0.481
≥4 comorbidities 173 (17.3) 368 (18.5) 0.421
Comedications
a 0.041*
Number of ATC classes 7.7±4.5 7.3±4.2
≤7 classes, n (%) 538 (53.7) 1,130 (56.8)
>7 classes, n (%) 463 (46.3) 859 (43.2)
Quantitative variables are presented as mean values±standard deviations and categorical variables as absolute patient numbers (percent)
BMI body mass index, BMD bone mass densitometry
*p<0.10, significant differences between the two treatment regimens
aBased on osteoporosis treatment initiation and prior 6 months
Osteoporos Int (2010) 21:145–155 149two cohorts, notably drugs used for functional gastrointestinal
disorders (19.3% in the monthly group and 16.3% in the
weekly group), systemic antibacterial drugs (23.9% and
19.3%, respectively) and antineoplastic drugs (0.3% and
1.2%, respectively). In addition, calcium or vitamin D
supplementation (53.0% in the monthly group versus 57.6%
in the weekly group) and other mineral supplementation
(56.1% in the monthly group versus 60.9% in the weekly
group) were more frequently used in the weekly regimen
group (p=0.017 and p=0.013, respectively).
Patient follow-up
Following the index prescription, patients treated with
monthly ibandronate were followed up for an average of
189 days and those treated with weekly bisphosphonates for
an average of 197 days. In the weekly group, 14.0% of
patients had been followed up for less than 3 months,
compared to 17.9% in the monthly group. The corresponding
proportions of patients followed up for more than 9 months
were 38.0% for weekly treatment and 34.0% for monthly
treatment. The mean treatment cover of an individual
prescription was 69 days in the weekly cohort and 75 days
inthe monthly cohort, with39.5% and46.9%,respectively, of
prescriptions covering at least 3 months.
Adherence to bisphosphonate treatment
Survival analysis demonstrated treatment persistence to
be significantly longer (p<0.0001) in the monthly
bisphosphonate cohort than in the weekly bisphosphonate
cohort (Fig. 2). Persistence rates at 6 months in the two
cohorts were 57.3% and 45.7% and fell to 47.5% and
30.4%, respectively, at 12 months. After propensity score
adjustment, women in the monthly group were 37% more
likely to persist than those in the weekly group (Table 2).
Sensitivity analyses were performed to assess the
impact of the attributed PG on the persistence rates
obtained. If an identical PG was allowed for both
treatment regimens, the difference in persistence at
1 year was reduced but remained significantly higher
(p<0.0001) for the monthly regimen. If a PG of 30 days
was allowed, persistence rates over 12 months were 38.0%
for the monthly regimen and 30.4% for the weekly
regimen (adjusted HR=0.77, 95%CI=0.69–0.86, p<
0.0001). If 45 days were allowed for both regimens, the
rates were 47.5% and 40.5%, respectively (adjusted HR=
0.78, 95%CI=0.69–0.89, p<0.0001).
Of the non-persistent patients, certain women discontinued
treatment definitively whilst others resumed their treatment at
a later date following a ‘drug holiday’. In the base case
scenario, 29.8% [95%CI=25.5% to 34.1%] of non-persistent
women in the monthly ibandronate cohort (13.0% of all
women in the cohort) and 31.3% [95%CI=28.5% to 34.1%]
in the weekly bisphosphonate cohort (16.2% of the entire
cohort) resumed treatment after a ‘drug holiday’ which
extended beyond the permissible gap. These proportions were
not significantly different between the two cohorts.
Similarly, compliance as measured by the mean MPR was
significantly lower (p<0.001) in the weekly cohort (Table 3),
with 65.8% of subjects presenting an MPR of ≥80%
compared to 74.1% in the monthly ibandronate cohort.
Determinants of persistence and compliance
to bisphosphonate treatment
Variables independently associated with persistence and
compliance with bisphosphonate treatment were identified
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Fig. 2 Kaplan–Meier analysis of treatment discontinuation with bisphosphonate. Thick line monthly ibandronate cohort, thin line weekly
bisphosphonates. A permissible gap of 45 days for monthly ibandronate and 30 days for weekly bisphosphonates was allowed in this analysis
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sion retained five variables, of which four were common to
both models. Availability of baseline BMD data, monthly
treatment regimen and use of calcium or vitamin D
supplementation were associated with better persistence
and higher compliance, whereas a diagnosis of rheumatoid
arthritis was associated with worse persistence and compli-
ance. A diagnosis of neurological disease was associated
with better persistence and the use of topical products for
joint and muscular pain (ATC class: M02) with poor
compliance only.
Fracture incidence
During the follow-up period, a lower proportion of
patients in the monthly cohort (20 women; 2.0%)
reported an incident fracture than in the weekly cohort
(125 women; 6.3%). This difference remained signifi-
cant after adjustment for the propensity score, which
included major known risk factors for fracture, such as
age and prior fracture (HR=0.69, 95%CI=0.54–0.89,
p=0.0043).
Discussion
This retrospective pharmacoepidemiological study using a
large primary care database showed that adherence to a
monthly bisphosphonate treatment regimen is higher than
that to weekly regimens in post-menopausal women. This
association could be detected after adjustments for all other
available confounding factors. We observed that patients
treated with a monthly regimen were 37% less likely to be
non-persistent and were more compliant, with a 5% higher
absolute MPR, than women treated with weekly regimens.
Optimising treatment adherence to bisphosphonates is
crucial to minimising fracture risk [32]. Indeed, several
studies have shown that adherence to treatment is the major
determinant of its efficacy. For example, Siris et al. [33]
reported that patients with an MPR >80% who were
persistent (no permissible gap in refills for >30 days over
24 months) presented a reduction in fracture risk of 20% to
45% compared to patients who did not meet these
adherence goals. A patient registry study in The Netherlands
[13] revealed that non-compliant bisphosphonate use
(MPR <80%) was associated with a 45% increase in
Table 2 Median persistence duration and associated hazard ratios with bisphosphonate treatments for the base case analysis and for different
definitions of the permissible gap
Persistence models Median persistence duration (days) Hazard ratios (95%CI)
Monthly ibandronate (N=1,001) Weekly BP (N=1,989) Unadjusted Adjusted
a
Base case 265 169 0.63* (0.56–0.71) 0.63* (0.56–0.72)
Monthly regimen: PG=45 days
Weekly regimen: PG=30 days
Sensitivity analyses
Both PG of 30 days 184 169 0.76* (0.68–0.85) 0.77* (0.69–0.86)
Both PG of 45 days 265 211 0.77* (0.68–0.87) 0.78* (0.69–0.89)
PG permissible gap
*p<0.0001
aCox proportional hazard model adjusted by propensity score
Table 3 Compliance to bisphosphonate treatments over 12 months
MPR Monthly ibandronate (N=1,001) Weekly bisphosphonates (N=1,989) p value
Mean±SD (95% CI) 84.5±23.0 (83.1–85.9) 79.4±26.7 (78.2–80.5) <0.001
Adjusted
a mean±SD (95%CI) 84.5±25.9 (82.9–86.2) 79.3±25.7 (78.2–80.4) <0.001
<20% 20 (2.0%) 98 (4.9%) <0.001
20–<40% 61 (6.1%) 169 (8.5%)
40–<60% 85 (8.5%) 179 (9.0%)
60–<80% 93 (9.3%) 234 (11.8%)
≥80% 742 (74.1%) 1,309 (65.8%)
MPR medication possession ratio
aGeneral linear model adjusted by propensity score
Osteoporos Int (2010) 21:145–155 151fracture risk compared to compliant use and that patients
with an MPR <20% presented an increased fracture risk of
80% compared to those with an MPR ≥90%. Similarly, in
a Canadian healthcare claims database [34], women with
an MPR <80% presented a relative risk of hip fracture of
1.28 compared with more compliant women. In these
studies, the thresholds for optimal MPR were defined a priori.
In a recent case–control study, we attempted to determine
empirically the thresholds of persistence and MPR associated
with optimal protection against fracture [31] and found that a
threshold MPR of 68% was the most discriminant for
fracture protection. Fracture risk was reduced by 51% in
women who achieved this threshold compared to less
compliant women. Concerning persistence, the optimal
threshold was at least 6 months of drug therapy.
In this context, it is possible that the increased
compliance and persistence associated with the use of
monthly administration observed in the present study could
provide a clinically relevant reduction in the risk of
fracture. Indeed, the observed fracture rates were signifi-
cantly lower (p=0.0043) in the monthly treatment group
(2% versus 6.3% in the weekly treatment group) and this
remained significant after adjustment for the propensity
score. This score included many important fracture risk
factors, such as BMI, previous fracture history and age, but
not all of these (for example, family history of osteoporotic
fracture and bone mass density were not included).
Nonetheless, prospective randomised comparative trials
would be useful to quantify any correlation between
adherence and fracture outcome for different bisphospho-
nate treatment regimens, and the observation of the current
study should only be regarded as hypothesis-generating.
Even with monthly administration, adherence to
bisphosphonate treatment remains largely suboptimal, and
strategies are needed to improve this. A number of methods
to improve persistence to oral bisphosphonates have indeed
been suggested. For example, offering bone densitometry to
women treated with bisphosphonates has been found to be
associated with a lower probability of discontinuation [35],
although there is no evidence that the BMD change, if any,
is directly related to anti-fracture effectiveness. Moreover,
the impact of offering densitometry may be limited, since
the largest loss of patients to treatment occurs within the
first 6 months of prescription, an interval in which bone
densitometry is neither recommended nor proposed. Others
have suggested the utility of biochemical markers to
provide patients with feedback on treatment effectiveness
[36], but such markers are not determined in routine clinical
practice. Improving patient communication on the impor-
tance of treatment and use of reminder systems is clearly
important. For example, Briot et al. [37] reported that
osteoporotic women starting therapy with a parathyroid
hormone analogue who enrolled in an education and
follow-up programme could achieve 15-month persistence
rates >80%.
It should be noted that non-persistence, as defined in this
and other studies, is not necessarily equivalent to treatment
discontinuation, as patients may lapse and then resume
treatment after a ‘drug holiday’ of variable duration. Given
the long half-life of bisphosphonates in bone tissue, such
women may continue to gain some benefit from their
treatment even if they go on ‘drug holidays’. Although such
behaviour was not studied in detail here and would merit
evaluation in a study with considerably longer follow-up
duration, it is unlikely that the differences in persistence
observed in our study could be accounted for by ‘drug
holidays’, as the proportion of women who did this was
relatively low and similar between the two cohorts.
An important potential confounding factor in any
comparison of adherence between different treatment
regimens is that patients prescribed one or other regimen
may be different. Indeed, in the present study, we found,
for example, that women prescribed monthly bisphosph-
onates tended to be younger and less likely to have
Odds ratio 95%CI
Determinants of persistence
BMD available 1.84* 1.43–2.37
Monthly regimen 1.57* 1.29–1.91
Neurological disorder 1.30*** 1.06–1.59
Calcium or vitamin D intake 1.28** 1.06–1.54
Rheumatoid arthritis 0.37** 0.19–0.73
Determinants of compliance
Bone mass densitometry available 1.55** 1.18–2.04
Calcium or vitamin D intake 1.36** 1.12–1.65
Monthly regimen 1.28*** 1.04–1.58
Topical products for joint and muscular pain 0.73** 0.58–0.92
Rheumatoid arthritis 0.45** 0.25–0.81
Table 4 Determinants of
persistence (≥6m o n t h s )a n d
compliance (MPR ≥68%)
Data are presented as odds ratios
with their 95%CI determined by
stepwise logistic regression
*p<0.0001; **p<0.01; ***p<
0.05
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they were more likely to have undergone bone densi-
tometry. This probably relates to the fact that the women
could either receive a diagnosis on the basis of BMD or
on the basis of fracture. Since the proportion of women
with previous fractures was lower, they were de facto
more likely to have received a diagnosis on the basis of
low BMD, accounting for the higher use of bone
densitometry in this group. Women in the monthly group
were also more frequently receiving multiple comedica-
tions, which may have been an incentive for their
physicians to prescribe them less frequently administered
bisphosphonates.
These factors may themselves influence treatment
adherence and it is important that they be taken into
account in any adherence study. For this reason, we
performed multivariate analysis of our adherence data in
order to determine the influence of the treatment regimen
independently of that of such confounding factors. Both for
MPR and persistence rates, we found that the treatment
regimen was a highly significant independent determinant
of both MPR and persistence.
With respect to other variables independently associated
with persistence or compliance, our findings were broadly
consistent with previous reports. The influence of bone
densitometry on reinforcing adherence has been a consis-
tent finding of previous studies [16, 35], but is difficult to
interpret here as the outcome of the evaluation (T-score)
was not available. Calcium or vitamin D supplementation
has previously been reported to be associated with better
compliance and improved fracture outcome in the ICARO
study [38]. Such dietary supplementation may also be
indicative of higher motivation. Likewise, patients with a
neurological disorder (notably epilepsy, Alzheimer or
Parkinson’s disease) were more persistent than others,
which may reflect awareness of physicians about the high
risk of fracture in such patients [39–41], as well as, for
patients with epilepsy, a history of treatment for which
good adherence is critical. Topical products for joint and
muscular pain mainly correspond to non-steroidal anti-
inflammatory drugs. Those drugs could be prescribed for
their analgesic effects on pain related to fractures, such as
back pain with vertebral fractures. Relief of these symp-
toms may also lead patients to be less adherent to treatment
of osteoporosis. Even though the absolute number of
patients was low (70 patients in all), a significant
association between a diagnosis of comorbid rheumatoid
arthritis and low MPR and poor persistence was observed.
The interpretation of this finding is unclear, but in the
absence of further information on rheumatoid pathology, it
merits exploration in a dedicated study. It is noteworthy that
it has been previously reported that patients with rheuma-
toid arthritis taking oral glucocorticoids did not routinely
undergo bone densitometry or receive prescription medi-
cations for osteoporosis [42].
An important determinant of the validity of our findings
is the representativity of the source data. The Thales
database has been demonstrated to be a reliable source of
information in numerous previous studies in rheumatology
[19, 24] and in other fields of medicine [43–46]. In
addition, the proportions of patients with various comor-
bidities in our study sample are consistent with the known
prevalence of these diseases in women over 45.
This study has several limitations. Some of these are
linked to the use of a primary care registry as the data
source. The use of such databases for pharmacoepidemio-
logical studies has become popular of recent years, since it
allows access to information on a large number of patients
gathered in real-world conditions [3, 47]. However, it is not
possible to ascertain ascribed diagnoses and to ensure that
these are exhaustive. Moreover, data on many important
variables that may influence the risk of fracture and the
uptake of treatment, such as family history and lifestyle
factors, are not available. In our study, patients who
switched treatment have been excluded from the analysis,
and this may limit the extent to which the findings can be
generalised to all women starting an antiresorptive therapy
w i t hb i s p h o s p h o n a t e s .S u c hw o m e nm a ys w i t c ht oa
treatment that they consider more acceptable, with which
they may be more compliant. In our study, the proportion of
women who switched treatments within the following year
was 3%, lower than switch rates reported in previous
studies [35] and is unlikely to have introduced significant
bias. However, the adherence of switchers to their new
treatment merits a dedicated study. Finally, the definition of
an acceptable prescription refill gap for determining
persistence rates in the study was arbitrary, even though
this definition is known to exert a crucial influence on the
observed persistence. We have attempted to control for the
influence of confounders on the observed differences
between the monthly and weekly regimens by using
propensity scoring, but it is clearly possible that unidenti-
fied confounders for which data were not collected may
play a role. It should be noted that a criterion for inclusion
was that women should have consulted their GP during the
reference period, which may de facto enriched the study
population in more adherent patients. However, such a bias
is in principle non-differential between the two groups.
The study also presents a number of strengths. These
include the representativity of the study sample with respect
to primary care in France. In addition, multivariate analysis
was performed to take into account the influence of
potential confounding factors on the relationship between
treatment regimen and adherence. The fact that the
confounding factors identified were consistent with known
determinants of adherence supports the face validity of the
Osteoporos Int (2010) 21:145–155 153model. In addition, sensitivity analyses were performed to
determine the influence of the definition of the permissible
gap on the findings. A significant relationship between
treatment regimen and adherence was found with all
hypotheses, supporting the robustness of this relationship.
In conclusion, this study suggests that adherence to
bisphosphonates is superior using a monthly treatment
regimen than using a weekly one. This difference would
be expected to have major repercussions on fracture
protection in osteoporotic women using such treatments.
However, adherence remains suboptimal and other
interventions to improve adherence need to be identified
and implemented.
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